Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331434 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
A NA study of Breast Cancer, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT01331434 is a NA study of Breast Cancer that has completed, run by Roxane Laboratories. The registered enrollment target is 47 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01331434, a NA study of Breast Cancer, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fed conditions.
Conditions Studied
Interventions
- DRUG exemestane
Study Locations (1)
Missouri
- Bio-Kinetic Clinical Applications, Inc. - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01331434
The ClinicalTrials.gov registry entry for NCT01331434 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which exemestane is the first listed.
NCT01331434 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01331434 about?
NCT01331434 is a clinical study titled "Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions". The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fed conditions.
What is the current status of trial NCT01331434?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2004-10. Estimated completion is 2004-10.
What conditions does trial NCT01331434 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01331434?
The interventions under investigation include: exemestane (DRUG).
Who is sponsoring clinical trial NCT01331434?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01331434 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.